Page 37 - Hal Barron News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GSK's Jemperli approved by US regulator for endometrial cancer Thu, 22nd Apr 2021 21:06 (Alliance News) - GlaxoSmithKline PLC said Thursday the US Food & Drug Administration has approved Jemperli for for women with recurrent or advanced dMMR endometrial cancer. Dostarlimab, the medical name for Jemperli, is indicated for the treatment of adult patients with mismatch repair deficient, dMMR, recurrent or advanced endometrial cancer, as determined by an FDA approved test, that have progressed on or following prior treatment with a platinum containing regimen, GSK noted. It continued: "This in...

Subscription Notification We have noticed that there is an issue with your subscription billing details. Please update your billing details here Please update your billing information The subscription details associated with this account need to be updated. Please update your billing details here to continue enjoying your subscription. Your subscription will end shortly Please update your billing details here to continue enjoying your access to the most informative and considered journalism in the UK.

The arrival of activist investor Elliott Management on the doorstep of Glaxosmithkline's glistening headquarters in Brentford has caught Emma Walmsley and her team on the hop.  The pharmaceutical group is aware of investor disquiet about a lagging share price compared with peers on both sides of the Atlantic.  The crossover in valuations between its main UK counterpart Astrazeneca and GSK, previously regarded as the UK's top rated big pharma group, has underlined perceived under-performance. Under pressure: GSK shares have been a disappointment, dropping 14 per cent since Emma Walmsley too...

Dive Brief: GlaxoSmithKline will stop enrolling cancer patients into two mid-stage studies testing a closely watched cancer immunotherapy alongside Merck & Co.'s Keytruda, marking another setback for the British drugmaker's ambitions in oncology research. The decision followed a recommendation from an independent monitoring committee that oversees one of the trials. In a Wednesday statement, GSK said it will evaluate the "totality of the data" to determine the impact on its broader development plans for the drug, called feladilimab. Feladilimab is a top drug prospect for GSK, one of a class o...

The world's largest vaccine business has been on the sidelines of the pandemic response. GSK is facing an exodus of US vaccine scientists, with several dozen leaving in the past year. Former GSK employees expressed frustration with the company's bureaucracy and pandemic response. On a mild day in December 2016, GlaxoSmithKline executives snipped an orange ribbon, ushering in what they hoped would be a new chapter for the pharmaceutical giant. GSK had just helped the world respond to the viral scares of H1N1 and Ebola, and its leaders envisioned growing their swanky vaccine-research center in ...